A Phase 1 Study of Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Before or After Progression on Docetaxel
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2019
Price : $35 *
At a glance
- Drugs Crizotinib (Primary) ; Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 06 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated
- 14 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.